Shares of NovoCure (NVCR -0.92%) were sinking 15.5% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence. The decline stemmed primarily from the company's disappointing third-quarter update.
NovoCure reported net revenue in the third quarter of $133.6 million, up only 1% year over year. The average analysts' estimate was for Q3 revenue of $141.2 million. The company posted a net loss in the third quarter of $13.1 million, or $0.13 per share. This reflected significant deterioration from net income of $9.3 million, or $0.09 per share, in the prior-year period. It also missed the consensus estimate of a net loss of $0.07 per share.
One weaker-than-expected quarter isn't necessarily a cause for concern. However, NovoCure has underwhelmed for several consecutive quarters. Unsurprisingly, the healthcare stock is down more than 40% year to date.
There is some good news for NovoCure, though. Sales for the company's Tumor Treating Fields product, which uses electrical pulses to prevent cancer cells from dividing, are growing in international markets. The company also announced on Thursday that the last patient had been enrolled in its pivotal late-stage study targeting recurrent ovarian cancer.
NovoCure also has several potential catalysts on the way. The most important of those catalysts is the announcement of final data from a late-stage study targeting non-small cell lung cancer expected in 2022. NovoCure also plans to report data from two phase 2 studies targeting gastric cancer and recurrent glioblastoma next year.